BioCat's valued partner RayBiotech develops innovative, reliable research tools for the post-genomic age. Their mission is to provide cutting-edge array technologies for the discovery of disease-related protein biomarkers and key factors, the identification of new drug targets, and the advancement of personalized medicine.
Following the completion of the human genome sequence, researchers have been able to analyze the expression of a myriad of disease-related genes; however, many diseases result from abnormal protein expression, post-translational modification, or interaction with other biomolecules. Thus, an understanding of disease states cannot be obtained from genomic research alone. Ultimately, efficient, high-throughput protein analysis offers the most promising approach to understanding and treating disease.
In 2001, RayBiotech addressed this need by introducing the first commercially available cytokine antibody array. Since then, their product lines have expanded to include hundreds of arrays and immunoassays for efficient analysis of proteins involved in inflammation, angiogenesis, apoptosis, cell growth, and signal transduction.
The products are designed for the quantitative measurement of cytokines, chemokines, growth factors, phosphorylated targets, immunoglobulins and other immunological markers in a variety of species. They provide a fast, sensitive and economical method to quantify protein levels in different sample types including serum, plasma, urine, cell culture supernatants as well as cell and tissue lysates.
RayBiotech's comprehensive service programs include array testing services, biomarker discovery, peptide discovery, and custom assay development.